Search Results - Saunthararajah, Yogen

Refine Results
  1. 1
    Targets of opportunity for precision medicine

    Targets of opportunity for precision medicine by Saunthararajah, Yogen

    Published 2015
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  2. 2
    Targeting sickle cell disease root-cause pathophysiology with small molecules

    Targeting sickle cell disease root-cause pathophysiology with small molecules by Saunthararajah, Yogen

    Published 2019
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  3. 3
    Mysteries of partial dihydroorotate dehydrogenase inhibition and leukemia terminal differentiation

    Mysteries of partial dihydroorotate dehydrogenase inhibition and leukemia terminal differentiation by Saunthararajah, Yogen

    Published 2020
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  4. 4
    β-Hemoglobinopathies lead the way

    β-Hemoglobinopathies lead the way by Saunthararajah, Yogen

    Published 2021
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  5. 5
    Epigenetic modifier directed therapeutics to unleash healthy genes in unhealthy cells

    Epigenetic modifier directed therapeutics to unleash healthy genes in unhealthy cells by Jha, Babal K., Saunthararajah, Yogen

    Published 2021
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  6. 6
    5-aza-2′,2′-Difluroro Deoxycytidine (NUC013): A Novel Nucleoside DNA Methyl Transferase Inhibitor and Ribonucleotide Reductase Inhibitor for the Treatment of Cancer

    5-aza-2′,2′-Difluroro Deoxycytidine (NUC013): A Novel Nucleoside DNA Methyl Transferase Inhibitor and Ribonucleotide Reductase Inhibitor for the Treatment of Cancer by Daifuku, Richard, Hu, Zhenbo, Saunthararajah, Yogen

    Published 2017
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  7. 7
    Severe pyoderma gangrenosum caused by myelodysplastic syndrome successfully treated with decitabine administered by a noncytotoxic regimen

    Severe pyoderma gangrenosum caused by myelodysplastic syndrome successfully treated with decitabine administered by a noncytotoxic regimen by Saleh, Mostafa F. M., Saunthararajah, Yogen

    Published 2017
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  8. 8
    Fetal Hemoglobin Induction by Epigenetic Drugs

    Fetal Hemoglobin Induction by Epigenetic Drugs by Lavelle, Donald, Engel, James Douglas, Saunthararajah, Yogen

    Published 2018
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  9. 9
    Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells

    Differentiation therapy and the mechanisms that terminate cancer cell proliferation without harming normal cells by Enane, Francis O., Saunthararajah, Yogen, Korc, Murray

    Published 2018
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  10. 10
    High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects

    High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects by Ebrahem, Quteba, Mahfouz, Reda, Ng, Kwok Peng, Saunthararajah, Yogen

    Published 2012
    Get full text Get full text
    Text
    Save to List
    Saved in:
  11. 11
    Decitabine Suspends Human CD34(+) Cell Differentiation and Proliferation during Lentiviral Transduction

    Decitabine Suspends Human CD34(+) Cell Differentiation and Proliferation during Lentiviral Transduction by Uchida, Naoya, Hsieh, Matthew M., Platner, Charlotte, Saunthararajah, Yogen, Tisdale, John F.

    Published 2014
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  12. 12
    Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions

    Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions by Zavras, Phaedon D., Shastri, Aditi, Goldfinger, Mendel, Verma, Amit K., Saunthararajah, Yogen

    Published 2021
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  13. 13
    A non‐cytotoxic regimen of decitabine to treat refractory T‐cell large granular lymphocytic leukemia

    A non‐cytotoxic regimen of decitabine to treat refractory T‐cell large granular lymphocytic leukemia by Zawit, Misam, Gurnari, Carmelo, Pagliuca, Simona, Awada, Hassan, Maciejewski, Jaroslaw P., Saunthararajah, Yogen

    Published 2021
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  14. 14
    Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo

    Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo by Alcazar, Oscar, Achberger, Susan, Aldrich, Wayne, Hu, Zhenbo, Negrotto, Soledad, Saunthararajah, Yogen, Triozzi, Pierre

    Published 2011
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  15. 15
    Subchronic oral toxicity study of Decitabine (DAC) in Combination with Tetrahydrouridine (THU) in CD-1 Mice

    Subchronic oral toxicity study of Decitabine (DAC) in Combination with Tetrahydrouridine (THU) in CD-1 Mice by Terse, Pramod, Engelke, Kory, Chan, Kenneth, Ling, Yonghua, Sharpnack, Douglas, Saunthararajah, Yogen, Covey, Joe

    Published 2014
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  16. 16
    Tracking Decitabine Incorporation into Malignant Myeloid Cell DNA in vitro and in vivo by LC-MS/MS with Enzymatic Digestion

    Tracking Decitabine Incorporation into Malignant Myeloid Cell DNA in vitro and in vivo by LC-MS/MS with Enzymatic Digestion by Chilakala, Sujatha, Feng, Ye, Li, Lan, Mahfouz, Reda, Quteba, Ebrahem, Saunthararajah, Yogen, Xu, Yan

    Published 2019
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  17. 17
    Gender Differences in Cytidine Deaminase Expression/Activity Contributes to Decreased Cytidine Analog Half-life and Likely Contributes to Worse Outcomes with 5-azacytidine or Decitabine Therapy – Author Reply

    Gender Differences in Cytidine Deaminase Expression/Activity Contributes to Decreased Cytidine Analog Half-life and Likely Contributes to Worse Outcomes with 5-azacytidine or Decit... by Mahfouz, Reda, Koh, Lip Seng, Teo, Marissa, Chee, Chit Lai, Toh, Han Chong, Saunthararajah, Yogen

    Published 2013
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  18. 18
    Association of tumor and plasma microRNA expression with tumor monosomy-3 in patients with uveal melanoma

    Association of tumor and plasma microRNA expression with tumor monosomy-3 in patients with uveal melanoma by Triozzi, Pierre L., Achberger, Susan, Aldrich, Wayne, Crabb, John W., Saunthararajah, Yogen, Singh, Arun D.

    Published 2016
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  19. 19
    Molecular profiling of primary uveal melanomas with tumor-infiltrating lymphocytes

    Molecular profiling of primary uveal melanomas with tumor-infiltrating lymphocytes by Triozzi, Pierre L, Schoenfield, Lynn, Plesec, Thomas, Saunthararajah, Yogen, Tubbs, Raymond R, Singh, Arun D

    Published 2014
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:
  20. 20
    AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model

    AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model by Wunderlich, Mark, Mizukawa, Benjamin, Chou, Fu-Sheng, Sexton, Christina, Shrestha, Mahesh, Saunthararajah, Yogen, Mulloy, James C.

    Published 2013
    Get full text Get full text Get full text
    Text
    Save to List
    Saved in:

Search Tools: